Inflammation BiomarkersNCT07433998
Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function
A study testing Functional beverage enriched with ginger in people with Inflammation Biomarkers and Oxidative Stress, run by Javier Marhuenda at 1 site in Spain.
Trial summary
Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity. Read more about this study
- Who is it for?
- Ages 23 to 65 years
- Conditions the study is for
- Inflammation Biomarkers, Oxidative Stress, Cardiometabolic Risk Factors
- What is being tested?
- Functional beverage enriched with ginger
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteSpain
- Study dates
- 10 Mar 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female participants.
- Age between 23 and 65 years.
- Body mass index (BMI) > 27.5 kg/m².
- Absence of diagnosed chronic diseases.
- Not receiving pharmacological treatment or dietary supplementation on a regular basis.
- Ability to understand the study procedures and willingness to comply with study requirements.
Who cannot join
- Presence of acute or chronic diseases not specified in the inclusion criteria.
- Ongoing chronic pharmacological treatment or active use of dietary supplements.
- Major surgery within the previous three months.
- Current smokers or recent former smokers (less than six months since cessation).
- History of clinically relevant food allergies or eating disorders.
- Concurrent participation in another clinical trial or research study.
Show all 9Show fewer
- Pregnancy or breastfeeding.
- Following an active weight-loss diet.
- Investigator's judgment of unsuitability for study participation.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of the Effect of a Ginger-based Functional Beverage on Markers of Inflammation, Oxidative Stress, and Endothelial Damage.
Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.
Read the detailed description
The duration of the study will be 60 days, during which the investigational product or placebo will be consumed daily according to the assigned intervention. Participants will be randomly allocated to the different study arms following a double-blind design.
- Being tested
- Functional beverage enriched with ginger, Control beverage without ginger
- Keywords
- inflammation Biomarkers, Oxidative Stress, Randomized Controlled Trial, Ginger
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Functional beverage enriched with gingerDietary supplement
Functional drink enriched with ginger
Control beverage without gingerDietary supplement
Control beverage without ginger
| Study group | Role | What they receive |
|---|---|---|
| Ginger-supplemented beverage | Experimental | Daily consumption of the functional product enriched with ginger for 60 days. Receives: Dietary Supplement: Functional beverage enriched with ginger |
| Placebo beverage | Placebo comparator | Placebo beverage matched in appearance to the intervention for 60 days Receives: Dietary Supplement: Control beverage without ginger |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in serum interleukin-1 beta (IL-1β) levels
Evaluation on differences in serum IL-1β levels
Measured: Day 1 and Day 60
Change in serum interleukin-6 (IL-6) levels
Evaluation on differences in serum IL-6 levels
Measured: Day 1 and Day 60
Change in plasma homocysteine levels
Evaluation on differences in homocysteine levels
Measured: Day 1 and Day 60
Change in plasma fibrinogen concentrations
Evaluation on differences in fibrinogen concentrations
Measured: Day 1 and Day 60
Atherogenic index
Evaluation on differences in atherogenic index. Differences in the Atherogenic Index of Plasma (AIP), calculated as log (triglycerides/HDL-cholesterol), will be evaluated between the intervention and control groups. Additionally, pre-post changes in AIP will be assessed within each group.
Measured: Day 1 and Day 60
Secondary outcomes (10)
Change in total cholesterol
Evaluation on differences in total cholesterol leveles (mg/dL)
Measured: Day 1 and Day 60
Change in LDL-cholesterol
Evaluation on differences in LDL-cholesterol (mg/dL) levels
Measured: Day 1 and Day 60
Change in HDL-cholesterol
Evaluation on differences in HDL-cholesterol (mg/dL) levels
Measured: Day 1 and Day 60
Change in triglycerides
Evaluation on differences in triglycerides (mg/dL) levels
Measured: Day 1 and Day 60
Change in fasting plasma glucose
Evaluation on differences in fasting plasma glucosa (mg/dL) levels
Measured: Day 1 and Day 60
Change in body weight
Evaluation of differences in body weight (kg)
Measured: Day 1 and Day 60
Change in body mass index
BMI will be calculated from measured weight and height using the formula weight (kg) / height² (m²).
Measured: Day 1 and Day 60
Change in fat mass
Evaluation of differences in fat mass (%)
Measured: Day 1 and Day 60
Change in lean mass
Evaluation of differences in lean mass (%)
Measured: Day 1 and Day 60
Change in blood pressure
Measured as changes in systolic and diastolic blood pressure (mmHg)
Measured: Day 1 and Day 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start10 Mar 2026
- Primary completion31 May 2026
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Inflammation BiomarkersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Javier Marhuenda
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Javier Marhuenda, Universidad Católica San Antonio de Murcia
- Investigators
- JAvier Marhuenda Hernández, Principal investigator, Universidad Católica San Antonio de Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433998
- Sponsor's protocol ID
- CE022406
- Status last verified
- Oct 2026
- First submitted
- 19 Feb 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Effect of a Ginger-based Functional Beverage on Markers of Inflammation, Oxidative Stress, and Endothelial Damage.
- ClinicalTrials.gov ID
- NCT07433998
- Acronym / sponsor ID
- CE022406
- Keywords
- inflammation Biomarkers, Oxidative Stress, Randomized Controlled Trial, Ginger
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Javier MarhuendaUniversity, hospital or other
- Study start
- 10 Mar 2026 (actual)
- Primary completion
- 31 May 2026 (actual)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.
Detailed description
The duration of the study will be 60 days, during which the investigational product or placebo will be consumed daily according to the assigned intervention. Participants will be randomly allocated to the different study arms following a double-blind design.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ginger-supplemented beverage | Experimental | Dietary Supplement: Functional beverage enriched with gingerDaily consumption of the functional product enriched with ginger for 60 days. |
| Placebo beverage | Placebo comparator | Dietary Supplement: Control beverage without gingerPlacebo beverage matched in appearance to the intervention for 60 days |
Who may qualify
- Ages
- 23 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male and female participants.
- Age between 23 and 65 years.
- Body mass index (BMI) > 27.5 kg/m².
- Absence of diagnosed chronic diseases.
- Not receiving pharmacological treatment or dietary supplementation on a regular basis.
Key exclusion criteria (9 listed)
- Presence of acute or chronic diseases not specified in the inclusion criteria.
- Ongoing chronic pharmacological treatment or active use of dietary supplements.
- Major surgery within the previous three months.
- Current smokers or recent former smokers (less than six months since cessation).
- History of clinically relevant food allergies or eating disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Functional beverage enriched with gingerFunctional drink enriched with ginger | Dietary supplement | Ginger-supplemented beverage |
| Control beverage without gingerControl beverage without ginger | Dietary supplement | Placebo beverage |
Primary outcome
Change in serum interleukin-1 beta (IL-1β) levels
Time frame: Day 1 and Day 60
Evaluation on differences in serum IL-1β levels
Change in serum interleukin-6 (IL-6) levels
Time frame: Day 1 and Day 60
Evaluation on differences in serum IL-6 levels
Change in plasma homocysteine levels
Time frame: Day 1 and Day 60
Evaluation on differences in homocysteine levels
Change in plasma fibrinogen concentrations
Time frame: Day 1 and Day 60
Evaluation on differences in fibrinogen concentrations
Atherogenic index
Time frame: Day 1 and Day 60
Evaluation on differences in atherogenic index. Differences in the Atherogenic Index of Plasma (AIP), calculated as log (triglycerides/HDL-cholesterol), will be evaluated between the intervention and control groups. Additionally, pre-post changes in AIP will be assessed within each group.
10 secondary outcomes
Change in total cholesterol
Time frame: Day 1 and Day 60
Change in LDL-cholesterol
Time frame: Day 1 and Day 60
Change in HDL-cholesterol
Time frame: Day 1 and Day 60
Change in triglycerides
Time frame: Day 1 and Day 60
Change in fasting plasma glucose
Time frame: Day 1 and Day 60
Change in body weight
Time frame: Day 1 and Day 60
Change in body mass index
Time frame: Day 1 and Day 60
Change in fat mass
Time frame: Day 1 and Day 60
Change in lean mass
Time frame: Day 1 and Day 60
Change in blood pressure
Time frame: Day 1 and Day 60
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Related trials for Inflammation Biomarkers
Recruiting
Effect of Curcumin Topical Spray on Wound Healing After Tooth Extraction
Wound Healing, Alveolitis of Jaw
Not yet recruitingObservational study
Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational Study
Sepsis
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
RecruitingObservational study
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Not yet recruitingObservational study
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
Biomarkers, Acute Kidney Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
JAvier Marhuenda Hernández principal investigator
Universidad Católica San Antonio de Murcia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Functional beverage enriched with ginger in people with Inflammation Biomarkers and Oxidative Stress, run by Javier Marhuenda at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in serum interleukin-1 beta (IL-1β) levels (time frame: Day 1 and Day 60). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.